ライフサイエンスコーパス: Pasteur

1 Pasteur's early approaches to vaccine development, atten

2 The Crabtree index and Pasteur index quantify the responses of oxidative and gl

3 lly characterized from the Ames, Sterne, and Pasteur strains of B. anthracis.

4 DGA capsule from the surface of B. anthracis Pasteur within 5 min.

5 A recombinant vaccine containing Aventis Pasteur's canarypox vector (ALVAC)-HIV and gp120 alum de

6 nt primary vaccine trials of diluted Aventis Pasteur smallpox vaccine (APSV) demonstrated that immuni

7 cinated with a 1 : 5 dilution of the Aventis Pasteur smallpox vaccine.

8 ical trials of the smallpox vaccine (Aventis Pasteur) were conducted in healthy, vaccinia virus-naive

9 week after primary immunization with Aventis Pasteur smallpox vaccine.

10 BCG Pasteur had intermediate effects, and BCG Montreal was t

11 previously sequenced strains (AF2122/97, BCG Pasteur, H37Rv, and CDC1551) into 5 major "SNP cluster g

12 ectively 59% and 49% of ORFs of M. bovis BCG Pasteur and M. smegmatis mc(2) 155.

13 two species; namely, Mycobacterium bovis BCG Pasteur and Mycobacterium smegmatis mc(2) 155.

14 odel compared with subcutaneous M. bovis BCG Pasteur vaccination.

15 8(PE_PGRS)) found in Mycobacterium bovis BCG Pasteur, which is the BCG homologue of the M. tuberculos

16 rom substrains derived from the original BCG Pasteur strain after 1925.

17 ciently to distant organs, compared with BCG Pasteur and BCG Montreal.

18 and M. bovis bacillus Calmette-Guerin (BCG) Pasteur in vivo and in vitro.

19 nel, M. bovis bacillus Calmette-Guerin (BCG) Pasteur, and M. bovis BCG Montreal were compared.

20 iveness studies (assessing the Behringwerke, Pasteur/Merieux, and SmithKline Beecham formulations) yi

21 e greatest stimulatory capacity, followed by Pasteur 1173 and then Danish 1331.

22 with the International Spoligotype database (Pasteur Institute, Pointe a Pitre, Guadeloupe) demonstra

23 oxo-IgG 2.0 and Toxo-IgM, Sanofi Diagnostics Pasteur Platelia Toxo IgG and Toxo IgM, and bioMerieux V

24 85.6%, respectively; and Sanofi Diagnostics Pasteur Platelia Toxo IgM, 100 and 96.8%, respectively.

25 latex agglutination (LA) (Sanofi Diagnostics Pasteur, Guildford, Surrey, United Kingdom) by using 406

26 cterium bovis BCG (bacillus Calmette-Guerin, Pasteur).

27 Building on the historical Pasteur-Bechamp debates on the role of the "microbe" vs

28 effects such as acidosis caused by a hypoxic Pasteur effect (instead of low O(2) by itself) are neces

29 We should follow in Pasteur's footsteps by using basic research to develop b

30 Institut Pasteur in Cambodia, Institut Pasteur Paris, National In

31 Institut Pasteur in Cambodia, Institut Pasteur Paris, National Institutes of Health, WHO, Agenc

32 cases were detected in Conakry, the Institut Pasteur of Dakar, Senegal, deployed a mobile laboratory

33 ain number ATCC 700975) and in the Institute Pasteur collection (assigned strain number CIP 107346).

34 The Chair introduced "Pasteur's Quadrant" as a potentially useful paradigm for

35 f M. bovis BCG (Copenhagen, Glaxo, Japanese, Pasteur, and Tice), and two strains of virulent Mycobact

36 ude nerve tissue vaccines developed by Louis Pasteur and his colleagues in 1885.

37 sed in vertical programmes inspired by Louis Pasteur, while vying with early private humanitarian act

38 cose metabolism was first described by Louis Pasteur.

39 Medical officers incorporated Louis Pasteur's discoveries into their understanding of microo

40 obiota has been recognized since the days of Pasteur.

41 in nature has been ongoing since the time of Pasteur.

42 Sanofi Pasteur has developed a chimeric yellow fever-dengue, li

43 Sanofi Pasteur has developed a tetravalent dengue vaccine (TDV)

44 Sanofi Pasteur's TDV was well tolerated and induced full seroco

45 dilution of Wyeth Dryvax vaccine and Sanofi Pasteur smallpox vaccine, given that the resulting morbi

46 onducted in Asia and Latin America by Sanofi Pasteur has constituted an important step.

47 mL intramuscular; both vaccines from Sanofi Pasteur) were administered.

48 ic or monomeric rHA1 or with SU-H5N1 (Sanofi Pasteur) emulsified with Titermax adjuvant and were chal

49 uted Dryvax vaccine or 1 of 2 lots of Sanofi Pasteur smallpox vaccine and were evaluated for vaccinat

50 d part of the review, we focus on the Sanofi Pasteur dengue vaccine candidate, describing the steps f

51 ficant morbidity when used undiluted; Sanofi Pasteur, Inc., later identified approximately 85 million

52 onent GlaxoSmithKline and 5-component Sanofi-Pasteur formulations) yielded an overall aP vaccine effi

53 Ever since Pasteur noticed that tartrate crystals exist in two non-

54 entral focus of the molecular sciences since Pasteur, its province has previously been restricted to

55 tative cellulose synthases from Anabaena sp. Pasteur Culture Collection 7120 and N. punctiforme Ameri

56 tative cellulose synthases from Anabaena sp. Pasteur Culture Collection 7120 and Nostoc punctiforme A

57 negative control over glycolysis (-26%; the Pasteur effect).

58 Widal test was run at the hospitals and the Pasteur Institute.

59 sted for antimicrobial susceptibility at the Pasteur Institute in Ho Chi Minh City.

60 interested in antibodies as a postdoc at the Pasteur Institute in Paris and a proponent of the antige

61 s ago, when I spent a sabbatical year at The Pasteur Institute in Paris.

62 I was fortunate to meet Jacques Monod at the Pasteur Institute, and this became a turning point in my

63 ls and 61% and 100% for Widal testing at the Pasteur Institute.

64 , they are classified as separate STs by the Pasteur Institute MLST system, and an ST131 PCR method t

65 rmanent respiratory defect that bypassed the Pasteur effect (i.e., the inhibition of anaerobic fermen

66 in both melanocytes and melanoma cells (the Pasteur effect).

67 ein kinase cascade, that can account for the Pasteur effect in ischaemic heart muscle.

68 that both R3230Ac and FSA tumors retain the Pasteur effect, i.e., hypoxia triggers increased glycoly